All START locations operate under the leadership of highly trained physicians and staff with extensive experience in Phase I clinical trials research and are nationally recognized as leaders in cancer research and drug development.
At START, we provide quality data through timely enrollment of study participants. The Phase I research staff is comprised of a variety of specialized team members all dedicated entirely to the Phase I program, trained in Good Clinical Practices (GCP), and highly experienced in the field of oncology.
START researchers are among just a handful of scientists anywhere in the world who can claim direct involvement with the clinical development of 27 anticancer drugs that, in the past 25 years, have obtained FDA approval and are now considered a part of standard of care. These drugs include: Navelbine (Vinorelbine®), Mixtoxantrone (Novantrone®), Irinotecan (Camptosar®), Docetaxel (Taxotere®), Gemcitabine (Gemzar®), Topotecan (Hycamtin®), Trastuzamab (Herceptin®), Cetuximab (Erbitux®), Erlotinib (Tarceva®), Gefitinib (Iressa®), Sorafenib (Nexavar®), Panitumumab (Vectibix®), Temsirolimus (Torisel®), Lapatinib (Tykerb®), Bortezomib (Velcade®), Vorinostat (Zolinza®), Pemetrexed (Alimta®), Abiraterone (Zytiga®), Ixabepilone (Ixempra®), Cabazitaxel (Jevtana®), Eribulin (Halaven®), Trametinib (Mekinist®), Trastuzumab Emtansine (Kadycla®), Regorafenib (Stivarga®), Ziv-Aflibercept (Zaltrap®), Carfilzomib (Kyprolisv) Pembrolizumab (Keytruda®), and cemiplimab (Libtayo®).